UnitedHealth reported 12% year-over-year revenue growth in its most recent quarter and raised its full-year earnings outlook to $14.90 per share, up from $14.65. However, its medical care ratio climbed to 89.9%, compared with 82.3% two years ago, reflecting a sharp rise in medical expenses relative to premium revenue. That deterioration in operating margin contributed to a 35% stock value decline in 2025, even as the S&P 500 rose 16%. Investors will be watching whether management’s cost-management initiatives can bring the care ratio closer to historical levels.

In a six-month pilot program covering Oklahoma, Idaho, Minnesota and Missouri, UnitedHealth will aim to cut Medicare Advantage payment collection times for independent rural hospitals from under 30 days to under 15 days. The initiative is intended to strengthen cash flow for facilities serving sparsely populated regions and to develop best practices that could be rolled out nationwide. Insights from the pilot will inform potential expansions, as the company seeks to demonstrate commitment to rural health sustainability in the face of ongoing reimbursement and regulatory challenges.

Following its steep sell-off, UnitedHealth now trades at roughly 18 times trailing earnings, versus a five-year average multiple of 25. That valuation gap offers a margin of safety but also reflects investor concerns about a Department of Justice investigation into billing practices and a Senate Judiciary report alleging aggressive diagnosis-coding strategies that boosted federal Medicare Advantage payments. Until those inquiries conclude and expense ratios stabilize, the stock’s P/E multiple may remain muted despite long-term growth prospects.